Preventing Gastrointestinal Disturbance in Patients After Longitudinal Laparotomy.

Exclusion Criteria16

• Patient has a history of gastrectomy, total colectomy, stoma creation, short bowel syndrome.
• Patient has pre-operative ileus.
• Patient is taking opioid analgesics longer than two post-operative days, exceeding a dosing of 35 mg morphine equivalent per day.
• Chemotherapy treatment within 10 days after longitudinal surgery.
• Smoking during the hospital stay.
• Any contraindication as per summary of product characteristic for the usage of local anesthetics for PDC.
• History of uncontrolled (at the discretion of the Investigator) cardiovascular, renal and/or hepatic failure.
• History of severe allergic or anaphylactic reactions, especially to local anesthetics.
• Clinically significant (at the discretion of the Investigator) deviation from the normal laboratory values.
• Clinically significant (at the discretion of the Investigator) abnormal ECG.
• Intake of any class 1B antiarrhythmic drugs if used for antiarrhythmic purpose (e.g., Lidocaine, Mexiletine, Phenytoin) and of any class 3 antiarrhythmic drugs - Kalium channel blockers (e.g., Amiodarone, Dronedarone, Sotalol, Ibutilide, Dofetilide, Bretylium).
• Significant (at the discretion of the Investigator) symptomatic, viral, bacterial (including upper respiratory infection), or fungal (non-cutaneous) infection (especially with need of antibiotic treatment) within the past 2 weeks prior to study medication administration.
• Experimental agent within 30 days or ten half-lives, whichever is longer, prior to study medication administration.
• Pregnancy or planning to become pregnant during the study.
• Any other condition, which in the opinion of the Investigator precludes the patient's participation in the study.
• Patients with close affiliation with the Investigator or persons working at the respective study sites or patients who are an employee of the Sponsor.